,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,136 Summit Avenue,Montvale,NJ,07645,United States,201 351 0605,https://www.eompharma.com,Biotechnology,Healthcare,"Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.",3,"{'maxAge': 1, 'name': 'Dr. Irach B. Taraporewala B.S., M.S., Ph.D.', 'age': 66, 'title': 'CEO, Pres & Director', 'yearBorn': 1956, 'fiscalYear': 2021, 'totalPay': 265646, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.22,0.1511,0.1511,0.2799,0.22,0.1511,0.1511,0.2799,0.0,0.022332506,-0.42187503,18659,18659,3267,9060,9060,0.0,0.0,900,3000,1425600,0.151,0.94,0.29642,0.4375,0.0,0.0,USD,27417506,0.0,5700917,4193500,165946,147775,1536883200,1539561600,0.0396,0.94967,0.0,4.13,0.0396,-0.033,1640908800,1672444800,1664496000,-5127658,12.09,-0.64,1:10,1600214400,PNK,EQUITY,IMUC,IMUC,EOM PHARMACEUTICAL HLDGS INC,"EOM Pharmaceuticals Holdings, Inc.",1610116200,America/New_York,EDT,-14400000,0.27,none,551176,0.005,3049117,0.75,0.972,-4.4045,-1987797,-2785943,0.0,0.0,0.0,USD,
1,136 Summit Avenue,Montvale,NJ,07645,United States,201 351 0605,https://www.eompharma.com,Biotechnology,Healthcare,"Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.",3,"{'maxAge': 1, 'name': 'Mr. Wayne I. Danson CPA', 'age': 68, 'title': 'CFO & Treasurer', 'yearBorn': 1954, 'fiscalYear': 2021, 'totalPay': 150000, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.22,0.1511,0.1511,0.2799,0.22,0.1511,0.1511,0.2799,0.0,0.022332506,-0.42187503,18659,18659,3267,9060,9060,0.0,0.0,900,3000,1425600,0.151,0.94,0.29642,0.4375,0.0,0.0,USD,27417506,0.0,5700917,4193500,165946,147775,1536883200,1539561600,0.0396,0.94967,0.0,4.13,0.0396,-0.033,1640908800,1672444800,1664496000,-5127658,12.09,-0.64,1:10,1600214400,PNK,EQUITY,IMUC,IMUC,EOM PHARMACEUTICAL HLDGS INC,"EOM Pharmaceuticals Holdings, Inc.",1610116200,America/New_York,EDT,-14400000,0.27,none,551176,0.005,3049117,0.75,0.972,-4.4045,-1987797,-2785943,0.0,0.0,0.0,USD,
2,136 Summit Avenue,Montvale,NJ,07645,United States,201 351 0605,https://www.eompharma.com,Biotechnology,Healthcare,"Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.",3,"{'maxAge': 1, 'name': 'Mr. Eli  Goldberger', 'age': 32, 'title': 'Founder, Chairman & COO', 'yearBorn': 1990, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.22,0.1511,0.1511,0.2799,0.22,0.1511,0.1511,0.2799,0.0,0.022332506,-0.42187503,18659,18659,3267,9060,9060,0.0,0.0,900,3000,1425600,0.151,0.94,0.29642,0.4375,0.0,0.0,USD,27417506,0.0,5700917,4193500,165946,147775,1536883200,1539561600,0.0396,0.94967,0.0,4.13,0.0396,-0.033,1640908800,1672444800,1664496000,-5127658,12.09,-0.64,1:10,1600214400,PNK,EQUITY,IMUC,IMUC,EOM PHARMACEUTICAL HLDGS INC,"EOM Pharmaceuticals Holdings, Inc.",1610116200,America/New_York,EDT,-14400000,0.27,none,551176,0.005,3049117,0.75,0.972,-4.4045,-1987797,-2785943,0.0,0.0,0.0,USD,
3,136 Summit Avenue,Montvale,NJ,07645,United States,201 351 0605,https://www.eompharma.com,Biotechnology,Healthcare,"Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.",3,"{'maxAge': 1, 'name': 'Dr. Shalom Z. Hirschman M.D.', 'age': 86, 'title': 'Co-Founder, Chief Scientific Officer & Medical Director', 'yearBorn': 1936, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.22,0.1511,0.1511,0.2799,0.22,0.1511,0.1511,0.2799,0.0,0.022332506,-0.42187503,18659,18659,3267,9060,9060,0.0,0.0,900,3000,1425600,0.151,0.94,0.29642,0.4375,0.0,0.0,USD,27417506,0.0,5700917,4193500,165946,147775,1536883200,1539561600,0.0396,0.94967,0.0,4.13,0.0396,-0.033,1640908800,1672444800,1664496000,-5127658,12.09,-0.64,1:10,1600214400,PNK,EQUITY,IMUC,IMUC,EOM PHARMACEUTICAL HLDGS INC,"EOM Pharmaceuticals Holdings, Inc.",1610116200,America/New_York,EDT,-14400000,0.27,none,551176,0.005,3049117,0.75,0.972,-4.4045,-1987797,-2785943,0.0,0.0,0.0,USD,
